The short version
4 companies supply this market — a reasonable cushion if one runs into trouble.
Market view
tofacitinib · Tablet, Extended Release
5 marketed package NDCs · 4 active manufacturers
Most dispensed: CITRATE 5 mg · Tablet, Film Coated · #60 tablet, film coateds/bottle · CITRATE 11 mg · Tablet, Film Coated, Extended Release · #30 tablet, film coated, extended releases/bottle · CITRATE 11 mg · Tablet, Extended Release · #30 tablet, extended releases/bottle · CITRATE 10 mg · Tablet, Film Coated · #60 tablet, film coateds/bottle
Price range and competition
RSS: changes for this drugEvery company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.
Latest · Sep 2026 — typical price $2.19 · middle half $2.19–$2.19 · full range $2.19–$2.19 · 2 products · 3 companies
ⓘ How this was built
Data sources
- CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
- CMS Federal Upper Limit files (weighted AMP)
- FDA NDC Directory (openFDA) — maker roster
Method
Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
What changed in the last 90 days
Every detected change for tofacitinib, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- XeljanzAug 19, 2026Price upNADAC $103.9028 → $103.93842 per unit (+0.03%)
- XeljanzAug 19, 2026Price downNADAC $73.73221 → $73.66576 per unit (-0.09%)
- Xeljanz XrAug 19, 2026Price upNADAC $207.86716 → $207.88061 per unit (+0.01%)
- TofacitinibAug 15, 2026Mfr enteredGolden State Medical Supply, Inc. · tofacitinib
- TofacitinibAug 15, 2026Mfr enteredGolden State Medical Supply, Inc. · tofacitinib
- TofacitinibAug 15, 2026New productGolden State Medical Supply, Inc.
- TofacitinibAug 15, 2026New productGolden State Medical Supply, Inc.
- TofacitinibAug 12, 2026Mfr enteredGolden State Medical Supply, Inc. · tofacitinib
- TofacitinibAug 12, 2026New productGolden State Medical Supply, Inc.
- TofacitinibJul 25, 2026Mfr enteredAvKARE · tofacitinib
Same drug class
Other molecules FDA puts in Janus Kinase Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Tofacitinib in shortage right now?
- No. FDA does not currently list Tofacitinib in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Tofacitinib?
- 22 companies have marketed Tofacitinib in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
- What does Tofacitinib cost?
- The typical pharmacy pays about $2.19 per unit, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.